Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• Retail Employees Superannuation Trust opened a new position in Thermo Fisher Scientific, buying 17,927 shares valued at about $10.4 million. The stake makes TMO its 15th-largest holding and represents about 2.8% of its portfolio.
• Thermo Fisher continues to draw strong institutional interest, with hedge funds and other investors owning 89.23% of the stock. Large holders such as Vanguard, Capital World Investors, and Franklin Resources all increased their positions.
• Analysts remain generally positive on the stock despite some recent price-target cuts, with a consensus rating of Moderate Buy and an average target price of $616.10. The company also beat quarterly earnings and revenue estimates, reporting $5.44 EPS on $11.01 billion in revenue.

Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 17,927 shares of the medical research company's stock, valued at approximately $10,388,000. Thermo Fisher Scientific accounts for about 2.8% of Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust's holdings, making the stock its 15th biggest holding.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. Capital World Investors lifted its position in shares of Thermo Fisher Scientific by 7.4% during the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after purchasing an additional 26,425 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after purchasing an additional 1,028,125 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Thermo Fisher Scientific by 54.7% during the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after purchasing an additional 1,262,967 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TMO shares. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. TD Cowen decreased their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday, April 24th. Barclays decreased their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a report on Tuesday, April 14th. Finally, DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a "buy" rating and a $610.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $616.10.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $456.64 on Thursday. The company has a market capitalization of $169.70 billion, a PE ratio of 25.10, a P/E/G ratio of 1.98 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The company has a 50-day simple moving average of $479.12 and a two-hundred day simple moving average of $535.54. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the previous year, the firm earned $5.15 earnings per share. The company's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.